Effects of 5 ARBs on blood pressure, glucose and lipid metabolism, renal and heart function, and inflammation markers (Earnest)

UMIN ID: C000000442

Registered date:05/07/2006

Basic Information

• Health condition(s) or Problem(s) studied: Hypertension
• Date of first enrollment: 2006/07/01
• Target sample size: 300
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Losartan group Start with once-daily dosing of losartan 25-50 mg, and increase up to 50-100 mg if effect of losartan on the clinical parameters is insufficient.
Telmisartan group Start with once-daily dosing of telmisartan 20-40 mg, and increase up to 40-80 mg if effect of telmisartan on the clinical parameters is insufficient.
Candesartan group Start with once-daily dosing of candesartan 4-8 mg, and increase up to 8-12 mg if effect of candesartan on the clinical parameters is insufficient.
Valsartan group Start with once-daily dosing of valsartan 40-80 mg, and increase up to 80-160 mg if effect of valsartan on the clinical parameters is insufficient.
Olmesartan group Start with once-daily dosing of olmesartan 5-10 mg, and increase up to 10-40 mg if effect of olmesartan on the clinical parameters is insufficient.

Outcome(s)

• Primary Outcome: 1. Waist circumference 2. Blood pressure, Ambulatory blood pressure 3. FPG, IRI, HbA1c, (IRI, PG during OGTT) 4. Proteinuria, albuminuria, urinary creatinine, BUN 5. TC (or LDL-C), TG, HDL-C 6. BNP 7. hs-CRP, adiponectin 8. baPWV

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients already receiving ARBs Pregnant women, or women suspected of being pregnant Hyperkalemia Bilateral renal artery stenosis Patients with history of hypersensitivity to the administered ARB Patients with severe liver disorder (losartan) Patients with severe defect in biliary drainage from liver or severe hepatic disorder (telmisartan)

Related Information

• Primary Sponsor: Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine Department of Endocrinology and Metabolism
• Source(s) of Monetary Support: Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine Department of Endocrinology and Metabolism